Karyopharm director Michael G. Kauffman resigns effective March 22, 2022

Karyopharm Therapeutics Inc.

Michael G. Kauffman, M.D., Ph.D. resigned from the Board of Directors effective immediately.
Resignation is not due to any disagreement with the Company's operations, policies or practices.
No replacement for the departing director has been announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael G. Kauffman

Director

KPTI · Karyopharm Therapeutics Inc.

Effective: 2022-03-22
Filed: March 28, 2022, 7:59 PM ET

On March 22, 2022, Michael G. Kauffman, M.D., Ph.D. notified Karyopharm Therapeutics Inc. (the “Company”) of his resignation from the Board of Directors, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael G. Kauffman resigned as Director at Karyopharm Therapeutics Inc..

Action: resigned
Role: Director

Exact text from the filing

On March 22, 2022, Michael G. Kauffman, M.D., Ph.D. notified Karyopharm Therapeutics Inc. (the “Company”) of his resignation from the Board of Directors, effective immediately.

View on SEC.gov

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-086854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.